These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 1425790)

  • 21. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
    Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
    J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.
    Oostdijk W; Rikken B; Schreuder S; Otten B; Odink R; Rouwé C; Jansen M; Gerver WJ; Waelkens J; Drop S
    Arch Dis Child; 1996 Oct; 75(4):292-7. PubMed ID: 8984913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adult height in advanced puberty with or without gonadotropin hormone releasing hormone analog treatment.
    Couto-Silva AC; Adan L; Trivin C; Brauner R
    J Pediatr Endocrinol Metab; 2002 Mar; 15(3):297-305. PubMed ID: 11924932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
    Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
    Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
    Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
    Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.
    Klein KO; Barnes KM; Jones JV; Feuillan PP; Cutler GB
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4711-6. PubMed ID: 11600530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
    Antoniazzi F; Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Borrelli P; Osio D; Mengarda F; De Luca F; Tatò L
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
    Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Antoniazzi F; Borrelli P; Crisafulli G; Wasniewska M; De Luca F
    Eur J Endocrinol; 1999 Aug; 141(2):140-4. PubMed ID: 10427157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty.
    Paterson WF; McNeill E; Young D; Donaldson MD
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):626-34. PubMed ID: 15521967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment].
    Messaaoui A; Massa G; Tenoutasse S; Heinrichs C
    Rev Med Brux; 2005 Feb; 26(1):27-32. PubMed ID: 15816337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height.
    Comite F; Cassorla F; Barnes KM; Hench KD; Dwyer A; Skerda MC; Loriaux DL; Cutler GB; Pescovitz OH
    JAMA; 1986 May; 255(19):2613-6. PubMed ID: 3084811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
    Léger J; Reynaud R; Czernichow P
    J Pediatr; 2000 Dec; 137(6):819-25. PubMed ID: 11113839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Near final height after GnRH agonist treatment in central precocious puberty.
    Micillo M; Salerno M; Officioso A; Perna E; Gasparini N; Pisaturo L; Di Maio S
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():787-90. PubMed ID: 10969922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
    Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A
    Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
    Antoniazzi F; Cisternino M; Nizzoli G; Bozzola M; Corrias A; De Luca F; De Sanctis C; Rigon F; Zamboni G; Bernasconi S
    Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.